BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.
Overview
BioNTech SE (NASDAQ: BNTX) is still widely viewed as a COVID-19 vaccine maker, but that picture is quickly changing. The company has quietly built a broad late-stage cancer pipeline spanning multiple promising treatments for different cancer types.
With the stock trading below $100, investors may be overlooking the significant upside the company can deliver by expanding its oncology portfolio.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.